GSK plcLSE: GSK

GSK: Transfer of Treasury Shares

· Issued by GSK plc via RNS

Summary by 6ix AI

On November 20, 2026, GSK plc, a biopharma company, transferred 22,000,000 ordinary shares it held in treasury (its own shares kept by the company) to JPMorgan Chase Bank, N.A. These shares back 11,000,000 American depositary receipts (ADRs, US-traded certificates representing GSK shares) for the GlaxoSmithKline (US) Trust.

Key details

  • JPMorgan Chase Bank, N.A. is the depositary of GSK's ADR programme. The ordinary shares have a nominal value of 31¼ pence each.
  • The ADRs will be used to satisfy awards granted under GSK's Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan.
  • The Trust's trustee paid $47.82 per ADR, representing $23.91 per ordinary share. The payment was funded by a contribution to the Trust from GlaxoSmithKline LLC.
  • Following the transfer, GSK will hold 248,881,064 ordinary shares in treasury and have 4,067,451,066 ordinary shares in issue, excluding treasury shares. Total voting rights are 4,067,451,066.
  • Following the transfer, the percentage of voting rights attributable to the treasury shares is 6.12%.

6ix AI wrote this summary from the release below and checked it against the release.

GSK PLC
20 November 2026

Issued: 20 November 2026, London UK

Transfer of Treasury Shares

On 20 November 2026, GSK plc (the “Company”) transferred 22,000,000 ordinary shares of 31¼ pence each (“Ordinary Shares”) that were held by the Company in treasury (“Treasury Shares”) to JPMorgan Chase Bank, N.A., the depositary of the Company’s American depositary receipts (“ADR”) programme, to procure the issuance and transfer of 11,000,000 ADRs of the Company to the GlaxoSmithKline (US) Trust (the “Trust”), to be used to satisfy awards granted under the Company’s Deferred Annual Bonus Plan, Performance Share Plan and Share Value Plan. The consideration received from the trustee of the Trust, of $47.82 per ADR, representing $23.91 per Ordinary Share, was funded by a contribution to the Trust from GlaxoSmithKline LLC.

Following the transfer, the Company will hold 248,881,064 Ordinary Shares in treasury and have 4,067,451,066 Ordinary Shares in issue (excluding Treasury Shares).

The total number of voting rights in the Company is 4,067,451,066. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Company confirms that, in accordance with DTR 5.5.1R, following the above transfer the percentage of voting rights attributable to the Treasury Shares is 6.12%.

This announcement is made in accordance with the requirements of UK Listing Rule 9.8.2.

Notifications may be sent to company.secretary@gsk.com.

V A Whyte

Company Secretary

20 November 2026

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

GSK plc on 6ix

Earlier from GSK

All GSK news releases